Association between serum indoxyl sulfate levels with carotid-femoral pulse wave velocity in patients with chronic kidney disease.
Aged
Aged, 80 and over
Biomarkers
Carotid-Femoral Pulse Wave Velocity
Comorbidity
Cross-Sectional Studies
Disease Susceptibility
Female
Humans
Indican
/ blood
Kidney Function Tests
Logistic Models
Male
Middle Aged
Multivariate Analysis
Renal Insufficiency, Chronic
/ blood
Risk Factors
Vascular Stiffness
Arterial stiffness
carotid-femoral pulse wave velocity
chronic kidney disease
indoxyl sulfate
Journal
Renal failure
ISSN: 1525-6049
Titre abrégé: Ren Fail
Pays: England
ID NLM: 8701128
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
entrez:
4
5
2021
pubmed:
5
5
2021
medline:
12
11
2021
Statut:
ppublish
Résumé
The role of indoxyl sulfate (IS), an important protein-bound uremic toxin, in arterial stiffness (AS) in patients with chronic kidney disease (CKD) is unclear. We investigated the association between serum IS levels and AS in a cross-sectional study of 155 patients with CKD. Patients in the AS group was defined as carotid-femoral pulse wave velocity (cfPWV) value >10 m/s measured by a validated tonometry system (SphygmoCor), while values ≤10 m/s were regarded as without AS group Serum IS was measured by liquid chromatography-mass spectrometry analysis. Of these CKD patients, AS was present in 51 (32.9%) patients, who were older, had a higher rate of diabetes, higher systolic blood pressure (SBP), and higher IS levels compared to those without AS. By multivariable logistic regression analysis, IS (adjusted odds ratio [aOR] 1.436, 95% confidence interval [CI] 1.085-1.901, These finding demonstrate that in addition to older and higher SBP, a high serum IS level is a significant biomarker associated with AS in patients with CKD.
Sections du résumé
BACKGROUND
BACKGROUND
The role of indoxyl sulfate (IS), an important protein-bound uremic toxin, in arterial stiffness (AS) in patients with chronic kidney disease (CKD) is unclear.
MATERIALS AND METHODS
METHODS
We investigated the association between serum IS levels and AS in a cross-sectional study of 155 patients with CKD. Patients in the AS group was defined as carotid-femoral pulse wave velocity (cfPWV) value >10 m/s measured by a validated tonometry system (SphygmoCor), while values ≤10 m/s were regarded as without AS group Serum IS was measured by liquid chromatography-mass spectrometry analysis.
RESULTS
RESULTS
Of these CKD patients, AS was present in 51 (32.9%) patients, who were older, had a higher rate of diabetes, higher systolic blood pressure (SBP), and higher IS levels compared to those without AS. By multivariable logistic regression analysis, IS (adjusted odds ratio [aOR] 1.436, 95% confidence interval [CI] 1.085-1.901,
CONCLUSION
CONCLUSIONS
These finding demonstrate that in addition to older and higher SBP, a high serum IS level is a significant biomarker associated with AS in patients with CKD.
Identifiants
pubmed: 33941031
doi: 10.1080/0886022X.2021.1921797
pmc: PMC8110183
doi:
Substances chimiques
Biomarkers
0
Indican
N187WK1Y1J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
796-802Références
Nephrol Dial Transplant. 2009 Jul;24(7):2051-8
pubmed: 19164326
Circ Res. 2000 Sep 29;87(7):E10-7
pubmed: 11009570
Oxid Med Cell Longev. 2019 Apr 17;2019:2050183
pubmed: 31178953
Toxins (Basel). 2019 Dec 21;12(1):
pubmed: 31877718
J Thromb Haemost. 2007 Jun;5(6):1302-8
pubmed: 17403109
Arch Med Res. 2012 Aug;43(6):451-6
pubmed: 22885091
Hypertension. 2004 Feb;43(2):176-81
pubmed: 14698999
Am J Nephrol. 2009;29(6):551-7
pubmed: 19129694
Nephrol Dial Transplant. 2011 Mar;26(3):938-47
pubmed: 20884620
Clin J Am Soc Nephrol. 2011 Jan;6(1):30-9
pubmed: 20876676
Am J Hypertens. 2009 Jan;22(1):74-9
pubmed: 19023277
Am J Physiol Cell Physiol. 2012 Jul 15;303(2):C126-34
pubmed: 22555846
Eur Heart J. 2010 Oct;31(19):2338-50
pubmed: 20530030
Nutrients. 2020 Jul 21;12(7):
pubmed: 32708072
J Am Soc Nephrol. 2014 Sep;25(9):1897-907
pubmed: 24812165
Hypertension. 2010 May;55(5):1110-5
pubmed: 20212269
J Am Soc Nephrol. 2016 Jun;27(6):1837-46
pubmed: 26475595
Kidney Blood Press Res. 2004;27(2):121-6
pubmed: 15051932
Kidney Int. 2004 Feb;65(2):442-51
pubmed: 14717914
Nutrients. 2020 Sep 24;12(10):
pubmed: 32987670
J Hypertens. 2012 Mar;30(3):445-8
pubmed: 22278144
Curr Hypertens Rev. 2018;14(2):154-160
pubmed: 29651957
Med Sci Monit. 2015 Aug 21;21:2467-75
pubmed: 26295503
J Hum Hypertens. 2017 Mar;31(3):189-194
pubmed: 27604661
Int Angiol. 2009 Dec;28(6):490-5
pubmed: 20087288
Kidney Int Suppl. 1997 Nov;62:S23-8
pubmed: 9350673
Biomed Chromatogr. 2016 Nov;30(11):1782-1788
pubmed: 27129599
J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27
pubmed: 20338492
Hypertension. 2012 Dec;60(6):1451-7
pubmed: 23090769
Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2190-7
pubmed: 26563380
PLoS One. 2012;7(3):e34026
pubmed: 22479508
Clin J Am Soc Nephrol. 2009 Oct;4(10):1551-8
pubmed: 19696217
Toxins (Basel). 2019 Oct 11;11(10):
pubmed: 31614554
Lab Invest. 2012 Apr;92(4):488-98
pubmed: 22231736
Hypertension. 2009 Dec;54(6):1328-36
pubmed: 19884567
QJM. 2009 Mar;102(3):183-91
pubmed: 19129249
J Nephrol. 2007 Nov-Dec;20 Suppl 12:S45-50
pubmed: 18050143
Ann Intern Med. 2013 Jun 4;158(11):825-30
pubmed: 23732715